Protection of nascent competition at centre of FTC order on medical technology deal
The Federal Trade Commission is requiring medical device company Medtronic to divest a subsidiary of Intersect ENT that is alleged to be a nascent competitor to proceed with its $1.1 billion purchase of the medical technology company.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10